SELLAS Life Sciences Group Inc
SLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.38B
Close$
$0.65
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.38 Billion |
|---|---|
| Enterprise Value | $2.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 2.49 |
| Outstanding Shares | 189,183,620 |
Return
| Return on Equity | -23.58% |
|---|---|
| Return on Assets | -22.33% |
| Return on Invested Capital | -24.60% |
Valuation & Multiples
| P/E Ratio | -60.48 |
|---|---|
| PEG | -132.9 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -66.06 |
| Enterprise Value to Net Income | -69 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 13.5293▲ 1336.16% |
|---|---|
| Total Calls | 24,913▼ 99.81% |
| Total Puts | 337,055▼ 85.07% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.19%▼ 12.09% |
|---|---|
| Total Invested | $488.35M▲ 113.79% |
| Investors Holding | 93▼ 83.00% |
ESG Score
No data
About SELLAS Life Sciences Group Inc
7 employeesSELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Ketteri...